TY - JOUR
T1 - Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-Infected patients
T2 - The changes in opportunistic prophylaxis study
AU - Mussini, Cristina
AU - Pezzotti, Patrizio
AU - Govoni, Alessandra
AU - Borghi, Vanni
AU - Antinori, Andrea
AU - D'Arminio Monforte, Antonella
AU - De Luca, Andrea
AU - Mongiardo, Nicola
AU - Cerri, Maria Chiara
AU - Chiodo, Francesco
AU - Concia, Ercole
AU - Bonazzi, Lucio
AU - Moroni, Mauro
AU - Ortona, Luigi
AU - Esposito, Roberto
AU - Cossarizza, Andrea
AU - De Rienzo, Bruno
PY - 2000
Y1 - 2000
N2 - A multicenter open, randomized, controlled trial was conducted to determine whether primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis can be discontinued in patients infected with human immunodeficiency virus type 1 (HIV-1) whose CD4+ T cell counts have increased to >200 cells/mm3 (and who have remained at this level for at least 3 months) as a result of highly active antiretroviral therapy (HAART). Patients were randomized to either the discontinuation arm (i.e., those who discontinued prophylaxis; n = 355) or to the continuation arm (n = 353); the 2 arms of the study were similar in terms of demographic, clinical, and immunovirologic characteristics. During the median follow-ups of 6.4 months- (discontinuation arm) and 6.1 months (continuation arm) and with a total of 419 patient-years, no patient developed P. carinii pneumonia or toxoplasmic encephalitis. The results of this study strongly indicate that primary prophylaxis for P. carinii pneumonia and toxoplasmic encephalitis can be safely discontinued in patients whose CD4+ T cell counts increase to >200 cells/mm3 during HAART.
AB - A multicenter open, randomized, controlled trial was conducted to determine whether primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis can be discontinued in patients infected with human immunodeficiency virus type 1 (HIV-1) whose CD4+ T cell counts have increased to >200 cells/mm3 (and who have remained at this level for at least 3 months) as a result of highly active antiretroviral therapy (HAART). Patients were randomized to either the discontinuation arm (i.e., those who discontinued prophylaxis; n = 355) or to the continuation arm (n = 353); the 2 arms of the study were similar in terms of demographic, clinical, and immunovirologic characteristics. During the median follow-ups of 6.4 months- (discontinuation arm) and 6.1 months (continuation arm) and with a total of 419 patient-years, no patient developed P. carinii pneumonia or toxoplasmic encephalitis. The results of this study strongly indicate that primary prophylaxis for P. carinii pneumonia and toxoplasmic encephalitis can be safely discontinued in patients whose CD4+ T cell counts increase to >200 cells/mm3 during HAART.
UR - http://www.scopus.com/inward/record.url?scp=0008865073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0008865073&partnerID=8YFLogxK
U2 - 10.1086/315471
DO - 10.1086/315471
M3 - Article
C2 - 10823763
AN - SCOPUS:0008865073
VL - 181
SP - 1635
EP - 1642
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 5
ER -